Penumbra (PEN)
(Real Time Quote from BATS)
$205.03 USD
+0.62 (0.30%)
Updated Apr 29, 2024 01:08 PM ET
3-Hold of 5 3
C Value A Growth D Momentum C VGM
Company Summary
Headquartered in Alameda, CA, Penumbra, as a global healthcare company, designs, develops, manufactures and markets innovative products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It has a broad portfolio that addresses challenging medical conditions in markets with significant unmet needs.
The company was incepted in 2004. It has successfully developed, obtained regulatory approvals for, and introduced products into the neurovascular market since 2007, in the vascular market since 2013, in the neurosurgical market since 2014, and in the immersive healthcare market since 2020.
Penumbra continues to develop and build ...
Company Summary
Headquartered in Alameda, CA, Penumbra, as a global healthcare company, designs, develops, manufactures and markets innovative products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It has a broad portfolio that addresses challenging medical conditions in markets with significant unmet needs.
The company was incepted in 2004. It has successfully developed, obtained regulatory approvals for, and introduced products into the neurovascular market since 2007, in the vascular market since 2013, in the neurosurgical market since 2014, and in the immersive healthcare market since 2020.
Penumbra continues to develop and build its product portfolio, including thrombectomy, embolization, access and immersive healthcare technologies, while iterating on its currently available products.
Penumbra sells its products to healthcare providers primarily through direct sales organizations in the United States, most of Europe, Canada and Australia, as well as through distributors in select international markets.
The company has three major market classifications and seven brand product families.
The Neuro major market comprises Thrombectomy (with major brands like Penumbra System, RED, JET, ACE catheter), Embolization (Penumbra Coil 400), Access (Neuron, BENCHMARK) and Neurosurgical Tools (Artemis Neuro Evacuation Device). The Vascular market includes Thrombectomy (Indigo System), Embolization (Ruby Coil, LANTERN, POD). Under the Immersive Healthcare market, it has an Immersive 3D Computer-based Technology platform (Real Immersive System).
In the fourth quarter of 2023, the company made changes to its product revenue categories and from 2024 it will report its product revenues in the following categories: thrombectomy and embolization and access.
The company provided its neuro and vascular product revenues for the fourth quarter and full year 2023 for the last time.
In 2023, Vascular revenues (comprising 61.6% of total sales) grew 30.6% from 2022. Neuro revenues (38.4%) during this period grew 16.8% from the year-ago figure.
General Information
Penumbra, Inc
One Penumbra Place
Alameda, CA 94502
Phone: 510-748-3200
Fax: 510-748-3232
Web: http://www.penumbrainc.com
Email: investors@penumbrainc.com
| Industry | Medical - Instruments |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 3/31/2024 |
| Earnings Date | 5/7/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.42 |
| Current Year EPS Consensus Estimate | 2.85 |
| Estimated Long-Term EPS Growth Rate | 35.60 |
| Earnings Date | 5/7/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 204.41 |
| 52 Week High | 348.67 |
| 52 Week Low | 180.93 |
| Beta | 0.51 |
| 20 Day Moving Average | 294,964.31 |
| Target Price Consensus | 293.08 |
| 4 Week | -8.41 |
| 12 Week | -18.89 |
| YTD | -18.74 |
| 4 Week | -5.64 |
| 12 Week | -21.14 |
| YTD | -24.00 |
| Shares Outstanding (millions) | 38.76 |
| Market Capitalization (millions) | 7,922.48 |
| Short Ratio | NA |
| Last Split Date | NA |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 71.78 |
| Trailing 12 Months | 97.80 |
| PEG Ratio | 2.02 |
| vs. Previous Year | 375.00% |
| vs. Previous Quarter | 13.43% |
| vs. Previous Year | 28.69% |
| vs. Previous Quarter | 5.07% |
| Price/Book | 6.69 |
| Price/Cash Flow | 72.29 |
| Price / Sales | 7.48 |
| 3/31/24 | NA |
| 12/31/23 | 7.49 |
| 9/30/23 | 5.54 |
| 3/31/24 | NA |
| 12/31/23 | 5.60 |
| 9/30/23 | 4.10 |
| 3/31/24 | NA |
| 12/31/23 | 6.06 |
| 9/30/23 | 5.99 |
| 3/31/24 | NA |
| 12/31/23 | 3.49 |
| 9/30/23 | 3.41 |
| 3/31/24 | NA |
| 12/31/23 | 7.74 |
| 9/30/23 | 5.84 |
| 3/31/24 | NA |
| 12/31/23 | 8.59 |
| 9/30/23 | 4.08 |
| 3/31/24 | NA |
| 12/31/23 | 7.52 |
| 9/30/23 | 4.89 |
| 3/31/24 | NA |
| 12/31/23 | 30.55 |
| 9/30/23 | 28.61 |
| 3/31/24 | NA |
| 12/31/23 | 1.03 |
| 9/30/23 | 1.02 |
| 3/31/24 | NA |
| 12/31/23 | 0.02 |
| 9/30/23 | 0.02 |
| 3/31/24 | NA |
| 12/31/23 | 1.97 |
| 9/30/23 | 2.11 |